A phase 2/3 study might show whether teliso-A can do better than teliso-V.

The move follows promising but early data presented at ASCO.

Roche dumps another partnered asset.

PD-(L)1 x VEGF developments coinciding with ASCO overshadowed the conference proper.

Meanwhile, Ichnos Glenmark takes a different trispecific multiple myeloma approach.

BNT327 could rival Keytruda and Opdivo, but toxicity is worth watching.

Imdelltra seems headed for full approval, raising questions about Zai’s accelerated plan.

LY4170156 looks similar to Genmab’s rina-S, but cost Lilly a lot less.

Evopoint reveals intriguing but opaque first-in-human data for XNW27011.

Enhertu plus Perjeta shows a convincing progression-free survival benefit over a Perjeta triplet.